Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence Study of DOXIL/CAELYX from New Manufacturing Site in Advanced Solid Tumors
NCT02081495Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Aug 2014
- Primary completion
- Nov 2015
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 4
01
Overview
Phase 1, randomised, open-label trial of pegylated liposomal doxorubicin in solid tumor, ovarian cancer and breast cancer (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Maximum observed plasma concentration of encapsulated doxorubicin, Time to reach maximum observed plasma concentration of encapsulated doxorubicin and 1 more. Started Aug 2014; status: completed.
02
Drugs
pegylated liposomal doxorubicin
03
Conditions
solid tumorovarian cancerbreast cancer
Beyond the preview
Go deeper on NCT02081495.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02081495.